Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-Episode Psychosis-a Pilot Study

Condition(s) targeted: Schizophrenia

Intervention: Seroquel® (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Institut fuer anwendungsorientierte Forschung und klinische Studien gGmbH

Official(s) and/or principal investigator(s):
Peter Falkai, MD PhD, Study Director, Affiliation: Department of Psychiatry and Psychotherapy, GEORG-AUGUST-UNIVERSITY GÖTTINGEN, GERMANY
Thomas Wobrock, MD PhD, Principal Investigator, Affiliation: Department of Psychiatry and Psychotherapy, GEORG-AUGUST-UNIVERSITY GÖTTINGEN, GERMANY
Andreas Heinz, MD PhD, Principal Investigator, Affiliation: Department of Psychiatry and Psychotherapy, Charité Campus Mitte Berlin, Germany
Georg Juckel, MD PhD, Principal Investigator, Affiliation: Department of Psychiatry, Ruhr University Bochum, Germany

Overall contact:
Peter Falkai, MD PhD, Phone: ++49(0)551 396601, Email: pfalkai@gwdg.de

The purpose of this study is:

To investigate whether a treatment with quetiapine for six months in patients with first-episode psychosis may be effective in treating depressive symptoms.

To investigate whether a treatment with quetiapine for six months in patients with first-episode psychosis may be effective in mania-like symptoms and to evaluate the general efficacy in psychopathology as well as the safety and tolerability of quetiapine.

Official title: Single-Arm, Open-Label and Multicenter Phase IV Study: Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-Episode Psychosis - a Pilot Study

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome: Changes in the Hamilton Depression Rating Scale (HAMDS) from Baseline to Endpoint

Secondary outcome: Changes in the Young Mania Rating Scale,Changes in the Positive and Negative Syndrome Scale,Changes in the Clinical Global Impression Scale(CGI,Changes in the self assessment of depressive symptoms(Beck Depression Inventory) from Baseline to Endpoint.

Detailed description: Affective symptoms, in particular depressive symptoms are prevalent in up to 60% of all patients with schizophrenia. However, it is still uncertain whether depressive symptoms have a prognostic value, having previously been associated with both favorable and poor outcome. In addition, treatment of affective symptoms in patients with schizophrenia is difficult. There is some evidence that atypical antipsychotics such as quetiapine may contribute not only to a reduction in psychotic symptoms but also that these agents may produce an antidepressant effect in schizophrenia and may reduce suicidality. Most of these studies suffer from methodological limitations as the efficacy on affective symptoms has not been the primary target parameter. Concerning the prevalence of affective symptoms in first-episode psychosis knowledge is still poor. This is why we have developed a study design for a pilot-study on 60 patients with first-episode schizophrenia aiming to demonstrate that a treatment with quetiapine over the period of 6 months shows clinical efficacy on affective, particularly depressive symptoms

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

All patients who meet the following inclusion criteria are eligible to participate in the study:

- male and female patients with first-episode schizophrenia (based on ICD-10 criteria)

- in- and out-patients

- age between 18 and 45

- verbal IQ 85

- given written informed consent

Exclusion Criteria:

Patients who meet one or more of the following exclusion criteria cannot participate in the study:

- Other Psychiatric disorders not in full remission, concomitant organic mental disorder

or mental retardation

- Patients who, in the investigators judgement, pose an imminent risk of suicide or a

danger to self or others

- Hamilton Depression Rating Scale<7 points

- Female patients who are pregnant, lactating or at risk of pregnancy

- Female patients who are not using a highly effective method of birth control. A highly

effective method of birth control is defined as those which results in a low failure rate (i. e. less than 1% per year) when used consistently and correctly such as implantants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner. For subjects using a hormonal contraceptive method, information regarding the product under investigation and its potential effect on the contraception must be addressed.

- history of idiopathic orthostatic hypotension, or condition that would predispose to

(dehydration, hypovolaemia)

- Risk of transmitting human immunodeficiency virus (HIV) or hepatitis B and C, via

blood or other body fluids

- history of non-compliance as judged by the investigator

- Patients with substance dependence. A urine drug screen will be performed. The

investigator will evaluate the results along with medical history to determine if the patient meets the DSM-IV criteria for substance dependence

- Patients with known diabetes mellitus or impaired glucose tolerance, especially a

patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:

- unstable DM defined as enrollment glycosylated hemoglobin (HbA1c)>8. 5%

- patients admitted to hospital for treatment of DM or DM related illness in past

12 weeks

- patients not under physicians care for DM

- physicians responsible for patient´s DM care has not indicated that patient´s DM

is controlled

- physician responsible for patient´s DM care has not approved patient´s

participation in the study

- patient has not been on the same dose of oral hypoglycemic drug(s) and/or diet

for the 4 weeks prior to randomization. (For thiazolidinediones (glitazones) this period should not be less than 8 weeks)

- patients taking insulin whose daily dose on one occasion in the past 4 weeks has

been more than 10% above or below their mean dose in the preceding 4 weeks.

Note: If a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study.

- ECG considered to show clinical significant abnormalities at enrolment as determined

by a cardiologist

- Use of drugs that induce or inhibit the hepatic metabolizing cytochrome 3A4 enzyme

within 2 weeks prior to randomization (e. g. inducers: phenytoin, carbamazepine, phenobarbital, rifampicin, rifabutin, glucocorticoids, thioridazine and St. Johns´wort (=Johanniskraut) and inhibitors: ketaconazole (except for topical use), itraconazole, fluconazole, erythromycin, clarithromycin, fluvoxamine, nefazodone, troleandomycin, indinavir, nelfinavir and saquinavir).

- patients with insufficient knowledge of the German language

- A thyroid-stimulating hormone (TSH) concentration more than 10% above the upper limit

of the normal range and the laboratory used for sample analysis at enrolment, whether or not the subject is being treated for hypothyroidism

- Any serious and unstable somatic illness (e. g. malignant tumor, severe cardiovascular

disease, etc.) that, in the opinion of the investigator, would be negatively affected by the study medication or that would affect study medication. If relevant medical findings are obtained during the examination, it is at the physician's discretion to initiate additional examinations (e. g. lab testing, ECG). If medically indicated examinations have already been carried out, the results should not be older than two weeks at the time of the screening visit. The patient can only participate in the study if all study results are within the normal range or the examiner has determined a deviation as clinically irrelevant. This should be clearly documented in the CRF.

- Participation in another drug trial within 4 weeks prior to enrolment into this study

or longer in accordance with local requirements

Peter Falkai, MD PhD, Phone: ++49(0)551 396601, Email: pfalkai@gwdg.de

Department of Psychiatry and Psychotherapy, GEORG-AUGUST-UNIVERSITY GÖTTINGEN, Göttingen, Germany; Recruiting
Peter Falkai, MD PhD, Phone: ++49(0)551 396601, Email: pfalkai@gwdg.de
Alexander Berg, Phone: ++49(0)551 3913498, Email: berg.ifs@med.uni-goettingen.de

Starting date: August 2007
Ending date: February 2010
Last updated: January 4, 2008